Table 2.

Veralipride efficiency with several evaluated schedules

	Schedule	N	Time	Study	Results
David36	A	47	2 months	Double blind, placebo controlled, crossover	Hot flush reduction 80% Residual effect 3 months after withdrawal
Wesel39	B	40		Double blind, randomized	Similar decrease in hot flushes between groups
Melis40	C	40	1 month	Randomized, double blind, placebo controlled	85% reduction
Vercellini41	D	36	2 months	Randomized, double blind, placebo controlled	Reduction 78% vs placebo 33%
Carranza-Lira7	E	75	3 months	Comparative, randomized, placebo controlled	80% reduction in frequency, 71% in intensity, 82% duration, sweats 66.6%
Morgante31	F	29	6 months	Randomized, comparative	Without differences between in number of hot flushes and Kupperman’s index Hot flushes decrease in 63% and 66% at 3rd and 6th month respectively
Boukobza42	G	166	3 months	Open, multicentric	Hot flush reduction 89.9% In 64.5% residual effect 3 months after withdrawal
Vercellini43	H	25	28 days	Open, observational trial	92% of patients have decrease in frequency and intensity of hot flushes
Marais44	I	–	1–14 months	Comparative, placebo controlled	48%–72% decrease

Notes: A, 100 mg/day for 20 days and 10 days drug free; B, 100 mg/day for 20 days and 10 days drug free versus conjugated estrogens 1.25 mg/day; C, 100 mg/day; D, 100 mg/day; E, 100 mg/day from Monday to Friday; F, Raloxifene plus veralipride in alternate days versus raloxifene and veralipride in alternate months; G, 100 mg/day for 20 days and 10 days drug free; H, 100 mg/day 20 days.